1-ethyl-4-(isocyanatomethyl)benzene | 518976-74-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-ethyl-4-(isocyanatomethyl)benzene
• CAS: 518976-74-4
• 化学式: C₁₀H₁₁NO
• mdl: MFCD11593154
• 分子量: 161.203
• InChiKey: HVJNCBQCVDQHAS-UHFFFAOYSA-N

物化性质

• 沸点：
  238.5±19.0 °C(Predicted)
• 密度：
  0.97±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-ethyl-4-(isocyanatomethyl)benzene 在 4-二甲氨基吡啶 、 苯甲醚 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 25.0h， 生成 4-[3,3-Diethyl-1-(4-ethyl-benzylcarbamoyl)-4-oxo-azetidin-2-yloxy]-benzoic acid
  参考文献：
  名称：

  Orally active .beta.-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones

  摘要：

  A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic beta-lactam and the mechanism of beta-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE. This work led to the identification of 4-[(4-carboxyphenyl)-oxy]-3,3-diethyl-1-[[(phenylmethyl)amino]carbonyl]-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE). Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model. Compounds with a methyl or a methoxy group in the para position of the benzene ring were very potent in both assays. The results are discussed on the basis of the proposed model for the binding of this class of inhibitors to HLE and a possible mechanism of inhibition is presented.

  DOI：

  10.1021/jm00099a003
• 作为产物：
  描述：

  2-(4-乙基苯基)乙酸 在 sodium azide 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 氯仿 、 水 、 丙酮 为溶剂， 反应 1.42h， 生成 1-ethyl-4-(isocyanatomethyl)benzene
  参考文献：
  名称：

  Orally active .beta.-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones

  摘要：

  A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic beta-lactam and the mechanism of beta-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE. This work led to the identification of 4-[(4-carboxyphenyl)-oxy]-3,3-diethyl-1-[[(phenylmethyl)amino]carbonyl]-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE). Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model. Compounds with a methyl or a methoxy group in the para position of the benzene ring were very potent in both assays. The results are discussed on the basis of the proposed model for the binding of this class of inhibitors to HLE and a possible mechanism of inhibition is presented.

  DOI：

  10.1021/jm00099a003

文献信息

• Alkyl Isocyanates via Manganese-Catalyzed C–H Activation for the Preparation of Substituted Ureas
  作者：Xiongyi Huang、Thompson Zhuang、Patrick A. Kates、Hongxin Gao、Xinyi Chen、John T. Groves

  DOI：10.1021/jacs.7b07658

  日期：2017.11.1

  range of functionalities. In this work, we have developed the first synthetic method for preparing aliphatic isocyanates via direct C-H activation. This method proceeds efficiently at room temperature and can be applied to functionalize secondary, tertiary, and benzylic C-H bonds with good yields and functional group compatibility. Moreover, the isocyanate products can be readily converted to substituted

  有机异氰酸酯是多功能中间体，可提供广泛的功能。在这项工作中，我们开发了第一种通过直接 CH 活化制备脂肪族异氰酸酯的合成方法。该方法在室温下有效进行，可用于官能化二级、三级和苄基 CH 键，具有良好的产率和官能团兼容性。此外，异氰酸酯产物无需分离即可轻松转化为取代脲，证明了该方法的合成潜力。为了研究反应机理，我们合成并表征了一种罕见的 MnIV-NCO 中间体，并证明了其将异氰酸酯部分转移到烷基的能力。使用 EPR 光谱，我们在催化条件下直接观察到了 MnIV 中间体。用手性锰盐催化剂异氰化天竺葵内酯，然后用苯胺捕集，得到对映体过量 51% 的尿素产品。这是通过 CH 活化不对称合成有机尿素的唯一例子。当结合我们的 DFT 计算时，这些结果清楚地表明 C-NCO 键是通过 MnIV-NCO 中间体捕获底物自由基形成的。
• Substituted Spiro Compounds and Their Use for Producing Pain-Relief Medicaments
  申请人：Frank Robert

  公开号：US20080269271A1

  公开（公告）日：2008-10-30

  The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments.

  本发明涉及替代螺环化合物，涉及制备这些化合物的方法，涉及含有这些化合物的药物以及利用这些化合物生产药物的用途。
• DIISOCYANATE COMPOSITION, PREPARATION METHOD THEREOF AND OPTICAL MATERIAL USING SAME
  申请人：SKC CO., LTD.

  公开号：US20210171451A1

  公开（公告）日：2021-06-10

  The diisocyanate composition according to an embodiment of the present invention comprises, in the composition, a benzyl isocyanate having a methyl group in an amount of 5 ppm to 200 ppm, an aromatic compound having a halogen group in an amount of 5 ppm to 1,000 ppm, a benzyl isocyanate having an ethyl group in an amount of 1 ppm to 1,000 ppm, or a combination thereof. It is possible to improve the optical characteristics by preventing the occurrence of yellowing, striae, and cloudiness and to enhance the mechanical properties such as impact resistance at the same time. Thus, it can be advantageously used to prepare an optical material of high quality.

  根据本发明实施例的二异氰酸酯组合物包括：在组合物中，含有甲基基团的苄基异氰酸酯，其量为5ppm至200ppm；含有卤素基团的芳香化合物，其量为5ppm至1,000ppm；含有乙基基团的苄基异氰酸酯，其量为1ppm至1,000ppm；或其组合物。通过防止黄变、条纹和浑浊的发生，可以改善光学特性，并同时增强冲击抗性等机械性能。因此，它可以优势地用于制备高质量的光学材料。
• Certain chemical entities, compositions, and methods
  申请人：Qian Xiangping

  公开号：US20080194633A1

  公开（公告）日：2008-08-14

  Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.

  本文描述了调节平滑肌肌球蛋白和/或非肌肉肌球蛋白的化学物质实体，制药组合物以及治疗与平滑肌肌球蛋白和/或非肌肉肌球蛋白相关的疾病和病状的方法。
• Substituted Spiro Compounds and their Use for Producing Drugs
  申请人：Schick Hans

  公开号：US20080214807A1

  公开（公告）日：2008-09-04

  The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments.

  本发明涉及取代的螺环化合物，涉及制备这些化合物的过程，涉及包含这些化合物的药物以及使用这些化合物制备药物的用途。